Literature DB >> 7726121

Perfusional and metabolic effects of nisoldipine as shown by positron emission tomography after acute myocardial infarction.

C Brunelli1, O Parodi, G Sambuceti, L Corsiglia, G M Rosa, A Giorgetti, G P Bezante, N Nista, S Caponnetto.   

Abstract

After myocardial infarction, regional dysfunction can occur in viable myocardial regions because of the presence of baseline hypoperfusion. Recent evidence suggests that these areas may maintain a residual perfusion reserve. The aim of the present study was to evaluate whether oral nisoldipine can increase regional myocardial blood flow (MBF) in dyssynergic but viable myocardium after myocardial infarction. Patients with isolated left anterior descending coronary stenosis were studied 1 month after the first myocardial infarction. Patients underwent [18F]fluorodeoxyglucose imaging, and MBF was measured, using positron emission tomography and [13N]ammonia, at baseline and following dobutamine administration (10 micrograms/kg/min over 5 minutes). MBF measurements were repeated 24 hours after nisoldipine (10 mg twice daily). Preliminary results suggest that necrotic areas showed the largest reduction in baseline MBF. Dyssynergic-viable regions showed a reduced resting MBF but maintained a residual perfusion reserve in response to inotropic stimulation. Thus, nisoldipine selectively improved basal perfusion in dyssynergic-viable myocardium.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7726121     DOI: 10.1016/s0002-9149(99)80445-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  2 in total

1.  Clinical application of three-dimensional myocardial imaging: evaluation of efficacy of medical treatment on myocardial perfusion.

Authors:  J Yamazaki; H Hosoi; S Ishiguro; H Muto; H Yamashina; T Morishita; M Takano; J Sugita; M Takahashi
Journal:  Ann Nucl Med       Date:  1996-11       Impact factor: 2.668

Review 2.  Nisoldipine coat-core. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of ischaemic heart disease.

Authors:  H D Langtry; C M Spencer
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.